胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展

doi:10.16352/j.issn.1001-6325.2022.08.1302

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (8): 1302-1305.doi: 10.16352/j.issn.1001-6325.2022.08.1302

胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展

赵茂宇¹, 李佑美¹, 刘焕云², 毛琦^1*

1.陆军军医大学第二附属医院心内科, 重庆 400037;
2.重庆市两江新区第一人民医院心内科, 重庆 401121

收稿日期:2021-04-15 修回日期:2021-08-13 出版日期:2022-08-05 发布日期:2022-08-01
通讯作者: ^*holygeneral1214@163.com

Research progress of insulin resistance markers in atherogenesis

ZHAO Mao-yu¹, LI You-mei¹, LIU Huan-yun², MAO Qi^1*

1. Department of Cardiology, the Second Affiliated Hospital of Army Medical University,Chongqing 400037;
2. Department of Cardiology, the First People's Hospital of Chongqing Liangjiang New Area, Chongqing 401121, China

Received:2021-04-15 Revised:2021-08-13 Online:2022-08-05 Published:2022-08-01
Contact: ^*holygeneral1214@163.com

摘要/Abstract

摘要： 胰岛素抵抗(IR)是连接代谢紊乱和动脉粥样硬化(AS)的关键枢纽。它在AS的启动和进展中发挥重要作用,其潜在机制涉及复杂的病理生理过程,包括内皮损伤、炎性反应激活及氧化应激。IR标志物显示了代谢风险和AS之间存在的潜在关联,检测IR标志物有利于心血管疾病的管理。

关键词: 胰岛素抵抗, 替代标志物, 动脉粥样硬化

Abstract: Insulin resistance (IR) is the pivotal link between metabolic disorders and atherosclerosis (AS). Insulin resistance plays an important role in the initiation and progression of atherosclerosis, and its underlying mechanism involves complex pathophysiological processes including endothelial injury, inflammatory reaction, and oxidative stress. Insulin resistance markers presented the potential association of metabolic risk with atherosclerosis and the detection of insulin resistance markers may support strategy development for the clinical management of cardiovascular diseases.

Key words: insulin resistance, surrogate markers, atherosclerosis

中图分类号:

R541.4

赵茂宇, 李佑美, 刘焕云, 毛琦. 胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1302-1305.

ZHAO Mao-yu, LI You-mei, LIU Huan-yun, MAO Qi. Research progress of insulin resistance markers in atherogenesis[J]. Basic & Clinical Medicine, 2022, 42(8): 1302-1305.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2022.08.1302

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2022/V42/I8/1302

参考文献 24

[1]	Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development[J]. Nat Rev Endocrinol, 2014, 10:293-302.
[2]	Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease[J]. Cardiovasc Diabetol, 2018, 17:122.doi:10.1186/s12933-018-0762-4.
[3]	Di Pino A, Defronzo RA. Insulin resistance and atherosclerosis:implications for insulin-sensitizing agents[J]. Endocr Rev, 2019, 40:1447-1467.
[4]	Saklayen MG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep, 2018, 20:12.doi:10.1007/s11906-018-0812-z.
[5]	Koren D, Taveras EM. Association of sleep disturbances with obesity, insulin resistance and the metabolic syn-drome[J]. Metabolism, 2018, 84:67-75.
[6]	Bornfeldt KE, Tabas L. Insulin resistance, hyperglycemia, and atherosclerosis[J]. Cell Metab, 2011, 14:575-585.
[7]	Biobaku F, Ghanim H, Batra M, et al. Macronutrient-mediated inflammation and oxidative stress:relevance to insulin resistance, obesity, and atherogenesis[J]. J Clin Endocrinol Metab, 2019, 104:6118-6128.
[8]	Schulman IG. Liver X receptors link lipid metabolism and inflammation[J]. FEBS lett, 2017, 591:2978-2991.
[9]	Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome[J]. Semin Immunopathol, 2018, 40:215-224.
[10]	Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease[J]. Cardiovasc Diabetol, 2018, 17:122.doi:10.1186/s12933-018-0762-4.
[11]	Onyango AN, Claudio C, Cabello-Verrugio C. Cellular stresses and stress responses in the pathogenesis of insulin resistance[J]. Oxid Med Cell Longev, 2018, 2018:4321714-4321727.
[12]	Zhao L, Varghese Z, Moorhead JF, et al. CD36 and lipid metabolism in the evolution of atherosclerosis[J]. Brit Med Bull, 2018, 126:101-112.
[13]	Glatz J, Luiken J. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization[J]. J Lipid Res, 2018, 59:1084-1093.
[14]	Son N, Basu D, Samovski D, et al. Endothelial cell CD36 optimizes tissue fatty acid uptake[J]. J Clin Invest, 2018, 128:4329-4342.
[15]	Deng Y, Li G, Chang D, et al. YKL-40 as a novel biomarker in cardio-metabolic disorders and inflammatory diseases[J]. Clin Chim Acta, 2020, 511:40-46.
[16]	Akboga MK. Increased serum YKL-40 level is associated with the presence and severity of metabolic syndrome[J]. Anato J Cardiol, 2016, 16:953-958.
[17]	Park HK, Kwak MK, Kim HJ, et al. Linking resistin, inflammation, and cardiometabolic diseases[J]. Korean J Intern Med, 2017, 32:239-247.
[18]	Helfer G, Wu Q. Chemerin:a multifaceted adipokine involved in metabolic disorders[J]. J Endocrinol, 2018, 238:R79-R94.
[19]	Zhang Z, Wang J, Wang H. Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus[J]. Exp Ther Med, 2018, 15:2936-2940.
[20]	Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance:past, present and future[J]. Crit Rev Clin Lab Sci, 2015, 52:180-190.
[21]	Ahmad R, Thomas R, Kochumon S, et al. Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity[J]. Immun Inflamm Dis, 2017, 5:318-335.
[22]	Gong Z, Zhang X, Su K, et al. Deficiency in AIM2 induces inflammation and adipogenesis in white adipose tissue leading to obesity and insulin resistance[J]. Diabetologia, 2019, 62:2325-2339.
[23]	Akbarzadeh M, Eftekhari MH, Dabbaghmanesh MH, et al. Serum IL-18 and hsCRP correlate with insulin resistance without effect of calcitriol treatment on type 2 diabetes[J]. Iran J Immunol, 2013, 10:167-176.
[24]	Bankul A, Mitra P, Suri S, et al. Increased serum IL-18 levels and IL-18R expression in newly diagnosed type 2 diabetes mellitus[J]. Minerva Endocrinol, 2020.doi:10.23736/s0391-1977.20.03271-x.

胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展

Research progress of insulin resistance markers in atherogenesis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱冰, 王旭. 斑点追踪成像技术在缺血性心脏病诊断中的应用[J]. 基础医学与临床, 2022, 42(9): 1459-1463.
[2]	刘珍竹, 李靖, 何丹, 曲鹏. PI3K信号通路调控动脉粥样硬化发生发展的研究进展[J]. 基础医学与临床, 2022, 42(9): 1428-1432.
[3]	谢思安, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 刘思. VAV1是动脉粥样硬化预后的潜在靶点和生物标志物[J]. 基础医学与临床, 2022, 42(7): 1092-1098.
[4]	许晓双, 闵行, 叶月, 郭梦然, 甄东户. 碘与代谢综合征相关性的研究进展[J]. 基础医学与临床, 2022, 42(6): 979-982.
[5]	郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉. 2型糖尿病心血管并发症发病机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 814-817.
[6]	裘耀扬, 桂家辉, 黄林, 虎学强, 李勤. 血管内光学相干层析成像技术在冠状动脉粥样硬化斑块检测方面的应用[J]. 基础医学与临床, 2022, 42(3): 360-365.
[7]	张爽, 李之凡, 钱杰, 吴娜琼. 腔内影像学方法评价降脂治疗对冠状动脉粥样硬化斑块影响的研究进展[J]. 基础医学与临床, 2022, 42(3): 366-371.
[8]	张琦悦, 张伟丽. 血管老化在动脉粥样硬化中的研究进展[J]. 基础医学与临床, 2022, 42(3): 372-377.
[9]	赵川榕, 周菁. 靶向剪切力敏感关键分子的动脉粥样硬化防治研究[J]. 基础医学与临床, 2022, 42(3): 378-383.
[10]	生燕, 李秀毛, 郭欣, 谢仟, 黄仁杰, 生欣. 兔颈动脉血流灌注减少促进血管内皮细胞炎性反应[J]. 基础医学与临床, 2021, 41(9): 1247-1252.
[11]	张传西, 张宇, 郭莎莎, 厉菁, 袁义强, 王明杰. 血清miR-181b和miR-27a表达与颈动脉粥样硬化程度相关[J]. 基础医学与临床, 2021, 41(8): 1133-1138.
[12]	唐百壹, 文娟, 唐晓鸿. ADAM17在动脉粥样硬化发病机制中作用的研究进展[J]. 基础医学与临床, 2021, 41(5): 744-748.
[13]	孙影, 董世云. 妊娠期代谢综合征对母亲健康及后代生长发育影响的研究进展[J]. 基础医学与临床, 2021, 41(10): 1518-1522.
[14]	冯冬萍, 商汉桥, 杨航, 张虎军, 张停, 杨梦溪, 屠强, 任景怡. 斑马鱼cetp基因敲除模型的建立及其肝脏转录组学分析[J]. 基础医学与临床, 2020, 40(7): 940-947.
[15]	杨卉, 莫显刚, 王兰, 张诗悦. ApoE^-/-小鼠动脉粥样硬化斑块中NHE1与Netrin-1表达上调[J]. 基础医学与临床, 2020, 40(6): 777-783.